Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it | ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...

“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...

Camrelizumab plus famitinib significantly improved PFS and OS compared to platinum-based chemotherapy in recurrent/metastatic cervical cancer. The trial reported a median PFS of 11.1 months for the ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

Mumbai: Doctors at Tata Memorial Hospital (TMH) have found that adding an affordable, decades-old platinum-based drug to ...

In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Among patients with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), treatment with ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...